BiologicalDrug
Olokizumab clinical trials
Also written CDP6038.
- studies test it
- 19
- open now
- 2
- in phase 3
- 9
- first study started
- 2008
Keep track of what changes. Save the olokizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
19 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 0
R-Pharm International, LLC (9) · UCB Pharma (4) · UCB BIOSCIENCES, Inc. (2) · R-Pharm (2) · UCB Japan Co. Ltd. (1) · UCB BIOSCIENCES GmbH (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses olokizumab is read from its arms, and is right about nine times in ten.
Testing it · 19
- Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisRecruitingPhase 2R-Pharm International, LLCNCT07517575Written as OKZ q4w
- Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesRecruitingPhase 2/3R-Pharm International, LLCNCT06440746Written as Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
- Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)Active, not recruitingPhase 3R-Pharm International, LLCNCT07670546Written as Olokizumab
- To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using MethotrexateCompletedPhase 1/2UCB PharmaNCT01009242Written as CDP6038
- Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4CompletedPhase 1R-Pharm International, LLCNCT04246762Written as Olokizumab
- Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) TherapyCompletedPhase 2UCB PharmaNCT01242488Written as CDP6038
- Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisCompletedPhase 3R-Pharm International, LLCNCT03120949Written as Olokizumab 64 mg SC q4w
- Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedPhase 3R-Pharm International, LLCNCT02760368Written as Olokizumab
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseCompletedPhase 3R-Pharm International, LLCNCT02760407Written as Olokizumab 64mg q4w
- Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active DiseaseCompletedPhase 3R-Pharm International, LLCNCT02760433Written as Olokizumab
- Study of Efficacy of Different Treatment Regimens of OlokizumabStatus unknownPhase 3R-PharmNCT05187793Written as Olokizumab
- The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid ArthritisTerminatedPhase 2UCB BIOSCIENCES, Inc.NCT01533714Written as CDP6038 (olokizumab)
- Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056TerminatedPhase 2UCB BIOSCIENCES, Inc.NCT01296711Written as CDP6038 (olokizumab)
- Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)CompletedPhase 2/3R-Pharm International, LLCNCT04380519Written as Olokizumab 64 mg
- Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).WithdrawnPhase 2/3R-PharmNCT04452474Written as Olokizumab 64 mg
- Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) TherapyCompletedPhase 2UCB Japan Co. Ltd.NCT01463059Written as Olokizumab 60 mg
- A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's DiseaseWithdrawnPhase 2UCB BIOSCIENCES GmbHNCT01635621Written as Olokizumab (OKZ)
- The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy MalesCompletedPhase 1UCB PharmaNCT01276119Written as CDP6038
- Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male SubjectsCompletedPhase 1UCB PharmaNCT01262794Written as CDP6038
As the comparator · 1 — what is tested is compared with olokizumab
Codes
What other systems call olokizumab · ClinicalTrials.gg INT000091
- MeSH (NLM) C000592400olokizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) PAI71R1D2WOLOKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7088501OlokizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C172654OlokizumabOne source FDA
- DrugBank DB13127One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592400 | olokizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | PAI71R1D2W | OLOKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7088501 | Olokizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C172654 | Olokizumab | One source FDA |
| DrugBank | DB13127 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.